28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech has announced the completion of phase 1 clinical trials of...
Pearce IP BioBlast for fortnight ending 28 June 2024
read more
Pearce IP is Australasian Lawyer’s 2024 Top Boutique Firm
We are thrilled to announce that Pearce IP has been honoured as Australasian Lawyer’s 2024 The Best Boutique Intellectual Property Law Firms in Australia!
Patenting Life Sciences Technologies
How claim types can influence enforcement strategies
How claim types and form will influence enforcement strategies
Patent Opposition Fails to Block Patent Term Extension for COPD and Asthma Drug
CQMS Triumphs in Patent Opposition Against ESCO Group
Pearce IP BioBlast for fortnight ending 14 June 2024
14 June 2024 | AU | Approval Alert: Bayer’s High Dose Eylea® (aflibercept) Approved in Australia On 14 June 2024, Australia’s Therapeutic Goods Administration (TGA) approved...
Don’t Dig Your Own Hole – Broad Claims and a Deficient Disclosure Can Lead to Support, Sufficiency and Utility Issues
CQMS Triumphs in Patent Opposition Against ESCO Group
8 Honours for Pearce IP and its Leaders in IAM Patent 1000 Guide
We are proud to announce that two of Pearce IP’s Leaders, Adele Chadwick and Chris Vindurampulle, have been honoured by WIPR Diversity Top 100 2024.
More than 70% of Pearce IP Patent Professionals Honoured in MIP’s IP Stars Guide
We are proud to announce that three of Pearce IP’s leaders have been recognised as MIP IP Stars for 2024. This prestigious accolade recognises Naomi Pearce, Helen Macpherson and Jacinta Flattery-O’Brien PhD for their exceptional contributions to the field of intellectual property.
Pearce IP BioBlast w/e 31 May 2024
31 May 2024 | EU | US | Europe’s CHMP Recommends Dupixent® (Dupilumab) as COPD Add-On Treatment On 31 May 2024, Regeneron and Sanofi announced that the Committee for Medicinal...
Carpark Saga Reaches Finale
SARB Management Group Pty Ltd trading as Database Consultants Australia v Vehicle Monitoring Systems Pty Limited (No 2) [2024] FCAFC 53
Pearce IP BioBlast w/e 24 May 2024
24 MAY 2024 | EU | Shanghai Henlius’ & Organon’s Biosimilar Denosumab Applications Validated by EMA On 24 May 2024, Shanghai Henlius and Organon announced that the European...
Pearce IP BioBlast w/e 17 May 2024
17 MAY 2024 | KR | New Indication Alert: MSD’s Keytruda® (Pembrolizumab) Approved in Korea for New NSCLC and Cervical Cancer Indications On 16 and 17 May 2024, respectively, the...
Leading IP Litigator Paul Johns joins Pearce IP signalling further growth in New Zealand
Pearce IP’s New Zealand Expansion Fueled by Commencement of Pre-Eminent IP Litigator Paul Johns from AJ Park
Navigating Post-Grant Patent Amendments: Lessons from R F Industries v Mine Site Technologies
R F Industries Pty Ltd v Mine Site Technologies Pty Ltd [2024] APO 16 provides a good example of the usefulness of re-examination and opposition to challenge a granted patent.
Pearce IP BioBlast w/e 10 May 2024
10 MAY 2024 | US | Valorum Biologics to Launch Xbrane and Stada’s Ranibizumab Biosimilar in the US On 10 May 2024, Xbrane and Stada announced the exclusive licensing agreement...
Pearce IP’s Leaders Honoured in WIPR Diversity’s Top 100 2024
Our Head of Talent has been honoured by WIPR as a Change Driver and is one of only 5 business services professionals ranked around the world, and is the only Australian honoured. Pearce IP’s Executive, Head of Patent Prosecution has been honoured by WIPR as a Diversity Champion, the only Australian recognised in this category.
Pearce IP BioBlast w/e 03 May 2024
03 MAY 2024 | CA | Lupin & Sandoz Launch Rymti® (etanercept) Biosimilar in Canada On 3 May 2024, Indian-headquartered Lupin, in partnership with Sandoz, announced its...
How’s Your Hamstring?
Vald Pty Ltd sued KangaTech Pty Ltd for patent infringement and Kanga cross-claimed alleging that Vald’s patent is invalid on the basis of lack of support, lack of sufficiency and lack of inventive step.
Zoetis Vaccine Patents’ Last Stand
Justice Rofe has delivered a further supplementary decision in the dispute between Boehringer Ingelheim Animal Health USA Inc (Boehringer) and Zoetis Services LLC (Zoetis) in relation to three Zoetis vaccine patent applications. Her Honour has now held the last remaining valid claim to be invalid for failure to disclose the best method of performing the claimed invention.
Naomi Pearce Nominated for 2024 IP Partner of the Year
We are delighted to announce that Pearce IP’s Founder and CEO, Naomi Pearce has been selected as a finalist for the 2024 IP Partner of the Year at the Lawyers Weekly Partner of the Year Awards.
Pearce IP BioBlast w/e 26 April 2024
29 APR 2024 | KR | Samil Pharmaceutical to Launch Samsung Bioepis’ Aflibercept in Korean Market from 1 May The Korean Biomedical Review has reported that Samil Pharmaceutical...
Pearce IP BioBlast w/e 19 April 2024
21 APR 2024 | US | Xbrane to Resubmit BLA for Ranibizumab Biosimilar following FDA CRL On 21 April 2024, Swedish biosimilar developer Xbrane announced that the FDA issued a...
The Carpark Patent Saga Continues – Infringement and Best Method
The Full Federal Court has overturned the primary judge’s decision on construction and infringement (with respect to PinForce version 3) but upheld the primary judge’s decision on best method, in the latest case to be heard and decided in the long-running patent disputes between arch rivals in the field of carpark overstay detection.
Pearce IP BioBlast w/e 12 April 2024
12 APR 2024 | US | Six Regeneron Aflibercept US Patent Infringement Actions to be Centralized in West Virginia On 11 April 2024, the United States Judicial Panel on...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.